| EGFR-216 G/T基因多态性与厄洛替尼治疗晚期非小细胞肺癌患者临床疗效的关系 |
| |
| 引用本文： | 李玉平,;张晓庆,;舒萍,;倪健,;张利斌,;徐丽丽.EGFR-216 G/T基因多态性与厄洛替尼治疗晚期非小细胞肺癌患者临床疗效的关系[J].中国药房,2014(34):3207-3210. |
| |
| 作者姓名： | 李玉平 ;张晓庆 ;舒萍 ;倪健 ;张利斌 ;徐丽丽 |
| |
| 作者单位： | [1]同济大学附属上海市肺科医院药剂科,上海200433; [2]同济大学附属上海市肺科医院肿瘤科,上海200433 |
| |
| 基金项目： | 上海医院药学科研基金项日资助（No.2010-YY-01-04） |
| |
| 摘 要： | 目的:探索表皮生长因子受体(EGFR)-216 G/T基因多态性与厄洛替尼治疗晚期非小细胞肺癌(NSCLC)临床疗效间的关系。方法:利用Sequenom MassArrayiPLEX GOLD系统对135例晚期NSCLC患者外周血EGFR基因启动子-216 G/T(rs712829)基因多态性进行检测。分析EGFR-216G/T位点的基因多态性与客观缓解率(RR)、疾病控制率(DCR)和无进展生存时间(PFS)的关系。结果:EGFR-216G/T基因频率为GG 81.5%(112/135),GT 11.9%(16/135),TT 6.6%(9/135)。EGFR-216G/T GG和GT+TT基因型RR之间差异有统计学意义(18.2%vs.48.0%,P=0.002);EGFR-216G/T GG和GT+TT基因型DCR之间差异有统计学意义(53.6%vs.76.0%,P=0.042);GG和GT+TT基因型之间中位PFS差异有统计学意义(3.95个月vs.6.80个月,P=0.038)。结论:EGFR-216G/T多态性与厄洛替尼治疗晚期NSCLC患者的疗效有相关性。EGFR-216G/T多态性可用于预测厄洛替尼治疗NSCLC患者的疗效。
|
| 关 键 词： | 表皮生长因子受体 基因多态性 非小细胞肺癌 疗效 相关性 |
Relationship of EGFR-216 G/T Gene Polymorphism with Clinical Efficacy of Erlotinib for Advanced NSCLC |
| |
| Institution: | LI Yu-ping, ZHANG Xiao-qing, SHU Ping, NI Jian, ZHANG Li-bin, XU Li-li( 1. Dept. of Pharmacy, Shang- hai Pulmonary Hospital, Tongji University, Shanghai 200433, China; 2. Dept. of Oncology, Shanghai Pulmo- nary Hospital, Tongji University, Shanghai 200433, China) |
| |
| Abstract: | OBJECTIVE： To investigate the relationship of epidermal growth factor receptor （EGFR）-216 G/T gene polymorphism with the clinical efficacy of erlotinib in the treatment of advanced non-small cell lung cancer （NSCLC）. METHODS： The polymorphisms of EGFR gene promoter -216 G/T （rs712829） from peripheral blood cell of 135 advanced NSCLC patients was detected by Sequenom MassArray iPLEX GOLD system. The relationship of EGFR-216 G/T gene polymorphism with response rate （RR）, disease control rate （DCR） and progression-free survival （PFS） was analyzed. RESULTS： The percentages of GG, GT and TT genotypes in EGFR-216G/T （rs712829） were 81.5% （112/135）, 11.9% （16/135） and 6.6% （9/135）, respectively. There was statistical significance in the difference of RR between GG and GT＋TT genotypes in EGFR-216G/T （18.2 % vs. 48.0%, P= 0.002 ）. There was statistical significance in the difference of DCR between GG and GT＋TT genotypes in EGFR-216G/T （53.6% vs. 76.0% ,P= 0.042）. There was statistical significance in the difference of PFS between GG and GT＋TT genotypes in EGFR -216G/ T （3.95 months vs. 6.80 months,P=0.038）. CONCLUSIONS： There is relationshiop between EGFR-216G/T gene polymorphism and clinical efficacy of erlotinib in the treatment of advanced NSCLC. EGFR -216G/T polymorphism is a potential predictor of clinical efficacy of erlotinib in the treatment of advanced NSCLC. |
| |
| Keywords: | EGFR Gene polymorphism NSCLC Therapeutic efficacy Relationship |
| 本文献已被 维普 等数据库收录！ |
|
